Arkolith/Insider Trading/PTGX/Form 4

Waddill William D.

DirectorProtagonist Therapeutics, Inc (PTGX) · full profile →Form 4 · filed Jun 25, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.1M
Net Open-Market Flow
-$1.1M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 23, 2026Option exercise(M)9K$16.54$149K17K
Jun 23, 2026Sell(S)9K$117.94$1.1M8K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 23, 2026Option exercise(M)9K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-077761) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML